Market Newsdesk

New Zillow standards: a listing marketed to any buyer must be available to every buyer

SEATTLE
, April 10, 2025 /PRNewswire/ — Zillow today announced new standards for listing transparency and already the tide is turning against the anti-consumer practice of encouraging sellers to list their homes off-market. eXp Realty, a vocal advocate for transparency in real estate and the number one brokerage by transaction count in the U.S., is the first to join Zillow and commit to posting listings in the Multiple Listing Service (MLS) within one day of publicly marketing to consumers and ensuring that eXp listings are on Zillow and available to the largest possible audience of buyers.

Zillow’s listing standards outline how Zillow is implementing the National Association of Realtors Clear Cooperation policy on our platform.  These standards state that a listing publicly marketed to any buyer must be in the MLS and published on Zillow as well as other sites that receive MLS feeds. We believe a listing available online anywhere consumers can see it must be online everywhere listings are displayed. Additionally, listings that don’t meet these standards won’t be published on Zillow and Trulia for the life of the listing. This policy is designed to ensure both consumers and agents have equitable, timely access to real estate information — supporting and protecting a more open and competitive housing market.

“eXp will always take a position that protects consumers first, that’s non-negotiable. We’re deeply committed to giving our clients the most transparent, comprehensive access to property listings in the market. Our new agreement with Zillow ensures that every eXp Realty listing has maximum visibility, creating a more efficient, trustworthy, and open marketplace,” said Leo Pareja, CEO of eXp Realty. “This partnership is about delivering value and building trust, two things that matter more than ever in today’s rapidly evolving real estate landscape. By tapping into Zillow’s massive consumer reach, eXp agents are positioned to serve more people and create more opportunity. At the end of the day, this is a strategic move that reflects our relentless commitment to innovation, agent empowerment, and delivering excellence for our clients.”

“It’s simple: sellers want exposure, and buyers deserve access,” said Errol Samuelson, chief industry development officer at Zillow. “When all buyers don’t have the same access to home listings — and are forced to navigate barriers, possible bias and incomplete inventory – it undermines consumer trust and weakens the market. From day one, Zillow has focused on unlocking real estate information for all. Zillow is committed to empowering brokerages and agents who are dedicated to raising the bar for access. This is why we invest in software and tech tools for real estate professionals, and why we stand up policies that move the industry forward – not back.”

Zillow and eXp Realty encourage other industry leaders — brokerages, MLSs, and tech platforms alike — to commit to transparent practices prioritizing access for all consumers and agents, not just a select few.

About Zillow Group:
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people. As the most visited real estate website in the United States, Zillow and its affiliates help people find and get the home they want by connecting them with digital solutions, dedicated real estate professionals, and easier buying, selling, financing, and renting experiences.

Zillow Group’s affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans℠, Zillow Rentals®, Trulia®, Out East®, StreetEasy®, HotPads®, ShowingTime+℠, Spruce®, and Follow Up Boss®.

All marks herein are owned by MFTB Holdco, Inc., a Zillow affiliate. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org). © 2025 MFTB Holdco, Inc., a Zillow affiliate.

(ZFIN)

View original content to download multimedia:https://www.prnewswire.com/news-releases/zillow-and-exp-announce-consumer-first-commitment-to-real-estate-transparency-302426044.html

SOURCE Zillow

NEW YORK
, April 10, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Lab USA, Inc. (NASDAQ: RKLB) between November 12, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important April 28, 2025 lead plaintiff deadline.

So what: If you purchased Rocket Lab securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Rocket Lab class action, go to https://rosenlegal.com/submit-form/?case_id=36018 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 28, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Rocket Lab’s plans for three barge landing tests were significantly delayed; (2) a critical potable water problem was not scheduled to be fixed until January 2026, which delayed preparation of the launch pad; (3) as a result of the foregoing, there was a substantial risk that Rocket Lab’s Neutron rocket would not launch in mid-2025; (4) Neutron’s only contract was made at a discount with an unreliable partner; and (5) as a result of the foregoing, defendants’ positive statements about Rocket Lab’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Rocket Lab class action, go to https://rosenlegal.com/submit-form/?case_id=36018 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rklb-investors-have-opportunity-to-lead-rocket-lab-usa-inc-securities-fraud-lawsuit-302425972.html

SOURCE THE ROSEN LAW FIRM, P. A.

NEW YORK
, April 10, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atkore Inc. (NYSE: ATKR) between February 1, 2024 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 23, 2025 lead plaintiff deadline.

So what: If you purchased Atkore common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Atkore class action, go to https://rosenlegal.com/submit-form/?case_id=35751 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 23, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) in turn, Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, Atkore and its price fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result of the above, defendants’ positive statements about Atkore’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Atkore class action, go to https://rosenlegal.com/submit-form/?case_id=35751 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/atkr-investors-have-opportunity-to-lead-atkore-inc-securities-fraud-lawsuit-302425979.html

SOURCE THE ROSEN LAW FIRM, P. A.

BOSTON
, April 10, 2025 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac’s Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed.  Heng Ren previously sent the Board a letter on March 19, and received no response.  The April 8 letter urges Sinovac to pay an additional dividend of $41 per share, which would pay shareholders a total of $96 per share and leave Sinovac with more than $1.3 billion net cash on hand – an amount more than sufficient for Sinovac’s operating needs.  Heng Ren encourages like-minded shareholders to visit https://www.hengreninvestment.com/sinovac-fairness/ and contact Sinovac directly.

The full text of the letter follows:

April 8, 2025

Dear Board of Directors:

I write on behalf of Heng Ren regarding our March 19, 2025 Shareholder Demand for Cash Distribution and Inspection of Books and Records (the “Shareholder Demand“) and the Company’s press release dated April 1, 2025 (the “Press Release“), in which the Board announced a special cash dividend of US$55.00 per common share (the “Dividend“).¹  Specifically, the Press Release stated that the Board expects to “fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operating subsidiaries of the Company.”  Heng Ren also notes that the Board announced that the “Dividend is intended to provide [Company] shareholders with their appropriate share of these prior distributions from the Company’s subsidiaries.”

Heng Ren is encouraged that the Board has announced the Dividend, which is consistent with its fiduciary obligations to allow shareholders finally to receive some benefit of their investment in Sinovac.  But more is required.  In order to increase transparency and trust, and ensure that Sinovac shareholders receive the benefit of their investment, the Board must immediately disclose the exact timing of the record and payment dates, and mechanics for the payment of the announced Dividend. This disclosure is especially critical given that shareholders still are unable to trade their shares due to the continued trading halt on the Nasdaq. The Board should also provide an update this week on the status of the resumption of trading of Sinovac’s stock as it is of critical importance to all shareholders. 

Furthermore, even after paying the Dividend, the Company still will be holding more than $6.3 billion in net cash and cash equivalents.  We see no rational business reason for the Company to continue to sit on that much cash.  The time to distribute the cash is now.  Therefore, the Board must not only cause the Company to pay the Dividend, but also cause the Company to pay an additional special dividend of $41 per share.  Such a dividend payment would leave the Company with more than $1.3 billion net cash on hand, an amount well above its operating needs. 

The issue of excess cash and its distribution is not only a matter of interest to shareholders like us. It also is of interest to the U.S. Securities and Exchange Commission (SEC).  As Heng Ren referenced in its letter dated March 19, 2025, in the correspondence from the SEC’s Division of Corporate Finance to Sinovac dated June 26, 2023, the SEC specifically asked the Company to describe “any restrictions and limitations on [its] ability to distribute earningsfrom the [C]ompany . . . to U.S. investors.”  In response, Sinovac did not identify any limitations on its ability to make distributions to investors, but simply stated it had no intention of distributing dividends in the near future.  At that time, the Company was sitting on more than $10.0 billion in net cash or cash equivalents.  This action (or inaction) precluded Sinovac’s shareholders from benefiting from the billions of dollars in cash that their investment had created.

Without a clear timeline on the payment of the announced $55 cash dividend, and Sinovac’s problem of excess cash still unaddressed, from a shareholders’ perspective the situation hasn’t changed since 2023 when the SEC sent its inquiry to Sinovac.

As demonstrated by the Company’s June 30, 2024 financial report, Sinovac’s cash on hand – without any revenue or operating cash flow, and after distribution of the $55 cash dividend –would finance nearly nine years of capital expenditures.

Sinovac can responsibly distribute not only the $55 cash dividend, but an additional special dividend of $41 per share.  The board and shareholders all should be aligned and in agreement for the distributions. These distributions pale in comparison to the opportunity cost of Sinovac’s shares being halted from trading when the Company’s value peaked in 2021. Long-oppressed shareholders now are entitled to receive this cash.

Heng Ren reiterates its previous demand to inspect and to make copies or extracts from, the books and records set forth in Section II.C (Parts 1-9) of its Shareholder Demand.

About Heng Ren:

Heng Ren Partners is a Boston-based asset management firm investing in Chinese companies.  Ropes & Gray LLP is serving as its legal counsel.

¹ Capitalized terms undefined herein shall have the same meanings ascribed to them in the Shareholder Demand.

View original content:https://www.prnewswire.com/news-releases/heng-ren-partners-calls-on-sinovac-to-disclose-the-record-and-payment-dates-of-the-special-dividend-and-distribute-an-additional-dividend-of-41-per-share-302426041.html

SOURCE Heng Ren Partners